コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 lications for the assessment and delivery of thrombolysis.
2 ution of thrombosis during catheter-directed thrombolysis.
3 on HT subtypes and outcome after intravenous thrombolysis.
4 mes in patients with mild stroke who receive thrombolysis.
5 tibility-weighted imaging before intravenous thrombolysis.
6 pannus and thrombus, the latter amenable to thrombolysis.
7 on making were both associated with desiring thrombolysis.
8 itive, and 2731 (38.5%) received intravenous thrombolysis.
9 reater benefit when treated with intravenous thrombolysis.
10 dimer, indicative of ongoing coagulation and thrombolysis.
11 often have a decline in blood pressure after thrombolysis.
12 mplications or do not respond to intravenous thrombolysis.
13 y (bond overstretching) during flow-mediated thrombolysis.
14 r of eligible patients receiving intravenous thrombolysis.
15 ation and increasing rates of catheter-based thrombolysis.
16 both parameters, which peaked 1-3 days after thrombolysis.
17 hemorrhagic transformation following stroke thrombolysis.
18 o randomisation, stroke-related factors, and thrombolysis.
19 e ischemic stroke who receive intra-arterial thrombolysis.
20 cological target of human ischemic stroke is thrombolysis.
21 eatment by mechanical thrombectomy and/or IA thrombolysis.
22 e onset within 4.5 hours, the time window of thrombolysis.
23 nts with an ischemic stroke are eligible for thrombolysis.
24 0.86 (0.81 to 0.91) and 0.85 (0.81 to 0.90); thrombolysis 0.85 (0.75 to 0.97) and 0.85 (0.75 to 0.97)
25 OR] = 0.21; 95% CI, 0.18-0.24), lower use of thrombolysis (12% vs 19% of those with ischemic stroke;
26 1 minutes]) and from the door to intravenous thrombolysis (32 minutes [IQR, 24-47 minutes]) were sign
27 vasive intervention (22 patients angioplasty/thrombolysis, 62 TIPS, and 20 OLT) and 36 (22.9%) died.
29 ng adjusted OR: 0.61; 95% CI: 0.60 to 0.62) (thrombolysis adjusted OR: 0.80; 95% CI: 0.78 to 0.82).
31 r comprehensive stroke management programme, thrombolysis administration increased and clinical outco
32 an states without similar stroke programmes, thrombolysis administration remained stable or declined
34 e patients would be treated with intravenous thrombolysis and 20 more with endovascular stroke therap
35 9), the reperfusion rate was 75.6% (34.4% by thrombolysis and 65.6% by primary percutaneous coronary
37 istently report a reduction in delays before thrombolysis and cause-based triage in regard to the app
38 anticoagulation, while interventions such as thrombolysis and inferior vena cava filters are reserved
39 chemic stroke but, to date, only intravenous thrombolysis and intra-arterial measures to restore perf
40 d to identify studies addressing the role of thrombolysis and mechanical thrombectomy in acute stroke
41 formed in 144 and 146 patients randomized to thrombolysis and placebo, respectively) did not reveal s
42 evels, and the development and timely use of thrombolysis and stents in acute coronary syndrome to li
43 nhibits tissue plasminogen activator-induced thrombolysis and subsequent reduction of ischemic brain
44 literature, we propose new ways to approach thrombolysis and suggest potential prophylactic and ther
45 vated glycoprotein IIb/IIIa allows effective thrombolysis and the potential novel use as a fibrinolyt
46 o block tissue plasminogen activator-induced thrombolysis and to obtain neuroprotection and inhibitio
47 ecanalization of the occluded artery through thrombolysis and/or endovascular thrombectomy is restric
48 n off-hours pattern (door-to-needle time for thrombolysis), and a flow pattern whereby quality change
52 amples were obtained prior to treatment with thrombolysis, and leukocyte RNA was assessed by microarr
54 reased the risk of PH 24 h after intravenous thrombolysis, and predicted poor clinical outcome indepe
55 efit of tissue plasminogen activator-induced thrombolysis; and 2) could be an efficient neuroprotecti
57 ng-term follow-up, 65 deaths occurred in the thrombolysis arm and 53 occurred in the placebo arm.
58 sessed in 353 of 359 (98.3%) patients in the thrombolysis arm and in 343 of 350 (98.0%) in the placeb
59 including time to neuroimaging and rates of thrombolysis, as well as outcomes, including death and d
60 ian NIHSS of 6.5 (range, 2-24), and received thrombolysis at a mean time of 10.3 +/- 2.6 LSN and 2.6
61 ase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST), we aimed to assess the efficacy a
62 ients with stroke cannot receive intravenous thrombolysis because the time of symptom onset is unknow
64 ur patterns of variation: a diurnal pattern (thrombolysis, brain scan within 12 h, brain scan within
65 n can be achieved mainly through intravenous thrombolysis, but other methods such as intra-arterial t
66 tion tube is more advantageous for efficient thrombolysis by enhancing cavitation-induced microstream
68 ) or anticoagulation plus pharmacomechanical thrombolysis (catheter-mediated or device-mediated intra
70 ctice patterns and role of catheter-directed thrombolysis (CDT) in the treatment of inferior vena cav
71 5 (7.4%) experienced a symptomatic ICH after thrombolysis, compared to 29/655 (4.4%) patients without
72 -needle (DTN) times </=60 minutes for stroke thrombolysis, critical DTN process failures persist.
73 d that physicians should not presume to make thrombolysis decisions for incapacitated patients with a
74 us medical management, including intravenous thrombolysis, demonstrated strong positive data in suppo
77 s in rates of teleconsultations, intravenous thrombolysis, endovascular stroke therapies, and spoke-t
79 he risk of ICH might outweigh the benefit of thrombolysis, especially in patients with multiple lobar
80 gh an evidence-based approach to intravenous thrombolysis for acute ischaemic stroke is pivotal, it i
82 tween this index and response to intravenous thrombolysis for AIS has not been properly evaluated.
83 lly invasive catheter evacuation followed by thrombolysis for clot removal is safe and can achieve a
84 cant increased risk of symptomatic ICH after thrombolysis for ischaemic stroke in patients with CMBs.
86 arise the value of immediate out-of-hospital thrombolysis for STEMI, and reconsider the potential the
87 ter experience with using pharmacomechanical thrombolysis for the treatment of thrombosed native arte
88 nd 96% in the conventional catheter-directed thrombolysis group (P = 0.33), and there was no differen
90 otic syndrome (47% in the pharmacomechanical-thrombolysis group and 48% in the control group; risk ra
91 in the ultrasound-assisted catheter-directed thrombolysis group and 54% +/- 27% in the conventional c
92 low-up period (12% in the pharmacomechanical-thrombolysis group and 8% in the control group, P=0.09).
93 in the ultrasound-assisted catheter-directed thrombolysis group and 96% in the conventional catheter-
94 yndrome were lower in the pharmacomechanical-thrombolysis group than in the control group at 6, 12, 1
95 in 18% of patients in the pharmacomechanical-thrombolysis group versus 24% of those in the control gr
97 treatment, patients who received golden hour thrombolysis had no higher risks for 7- or 90-day mortal
100 mage is the major risk factor for fatal post-thrombolysis ICH, but rapidly assessing BBB damage befor
101 otential to receive benefit from intravenous thrombolysis if they have favourable predictors of outco
102 ents with acute pulmonary embolism, systemic thrombolysis improves right ventricular (RV) dilatation,
103 ut maneuver in 9 cases (success rate, 100%), thrombolysis in 9 patients (success rate, 56%), and pump
107 ecommendations to treat ischemic stroke with thrombolysis in appropriate emergency circumstances unde
111 achieved angiographic reperfusion (score on Thrombolysis in Cerebral Infarction scale of grade 2-3)
112 sful revascularization defined as a modified Thrombolysis in Cerebral Infarction score of 2b or 3 at
114 Reperfusion was assessed with angiographic Thrombolysis in Cerebral Infarction scores at the end of
115 ilar in terms of substantial recanalization (Thrombolysis in Cerebral Ischemia scores 2B to 3; drip a
119 ranch block identified patients with reduced Thrombolysis in Myocardial Infarction (0-2) flow with 70
120 d in Patients with Diabetes Mellitus (SAVOR)-Thrombolysis in Myocardial Infarction (TIMI) 53 is a ran
123 nt elevation MI within 6 h of symptom onset, Thrombolysis In Myocardial Infarction (TIMI) flow grade
124 nset of symptoms within 12 hours, STEMI, and thrombolysis in myocardial infarction (TIMI) grade 0-1 f
125 The primary endpoint was a composite of Thrombolysis In Myocardial Infarction (TIMI) major and m
126 (MI), definite stent thrombosis, stroke, or Thrombolysis In Myocardial Infarction (TIMI) major bleed
127 ease in all non-coronary artery bypass graft Thrombolysis In Myocardial Infarction (TIMI) major bleed
128 ular death/myocardial infarction/stroke) and Thrombolysis in Myocardial Infarction (TIMI) major bleed
129 The rate of the key safety end point of all Thrombolysis in Myocardial Infarction (TIMI) major bleed
131 ram, Age, Risk Factors, Troponin (HEART) and Thrombolysis in Myocardial Infarction (TIMI) risk scores
132 thway integrating 0- and 2-h hs-TnI results, Thrombolysis In Myocardial Infarction (TIMI) risk scores
133 immediate stenting (n=73) or DS (n=67) after Thrombolysis In Myocardial Infarction 3 flow restoration
134 in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36) trial and foll
135 ptimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38
136 ptimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction 38) study prasugre
138 or Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) trial compared
139 or Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction 48) trial in patie
140 or Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction 48) trial, compari
141 or Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48), the factor Xa
142 evention of Atherothrombotic Ischemic Events-Thrombolysis in Myocardial Infarction 50 (TRA 2 degrees
143 and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2 degrees P
144 and Stroke in Patients With Atherosclerosis-Thrombolysis In Myocardial Infarction 50) was a multinat
145 Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51) trial, which d
147 Recorded in Patients With Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53]), alogliptin (
148 mpared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54) (ticagrelor) w
149 mpared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) randomized 21,
150 mpared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) trial studied
151 mpared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) trial, which r
152 mpared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54), in which 21,1
153 Clopidogrel by Involving a Genetic Strategy-Thrombolysis In Myocardial Infarction 56) investigators
154 body Inhibition Combined With Statin thErapy-Thrombolysis In Myocardial Infarction 57) trial at high
155 patients (58.7% female, age 59 +/- 13, 78.6% thrombolysis in myocardial infarction [TIMI] </=2), 9% h
156 ajor bleeding or minor bleeding according to Thrombolysis in Myocardial Infarction [TIMI] criteria or
157 to Open Occluded Coronary Arteries [GUSTO], Thrombolysis in Myocardial Infarction [TIMI], and Acute
158 RS-PR showed higher discriminatory power for thrombolysis in myocardial infarction bleeding than BRS
159 criminatory power of BRS-PR (AUC = 0.809 for thrombolysis in myocardial infarction bleeding; AUC = 0.
160 1.31; 95% CI: 1.16 to 1.48; p < 0.0001) and Thrombolysis In Myocardial Infarction blush grade (TBG)
165 arction thrombus grade; (2) postintervention thrombolysis in myocardial infarction flow and myocardia
167 ine at admission >132.6 mumol/l (1.5 mg/dl), Thrombolysis In Myocardial Infarction flow grade <3 afte
168 arameters such as blush grade (p = 0.63) and Thrombolysis In Myocardial Infarction flow grade (p = 0.
169 the proportion of patients who did not have Thrombolysis in Myocardial Infarction flow grade 3 in th
170 tion, is regularly lysing fibrin and induced Thrombolysis In Myocardial Infarction flow grade 3 paten
174 romboxane B2, reperfusion indexes (corrected Thrombolysis In Myocardial Infarction frame count and my
175 istically significant reduction in corrected Thrombolysis In Myocardial Infarction frame count more e
176 with pre-percutaneous coronary intervention Thrombolysis in Myocardial Infarction grade 0 to 1 flow,
178 ded non-coronary artery bypass graft-related Thrombolysis In Myocardial Infarction major and minor bl
179 ncreased non-coronary artery bypass grafting Thrombolysis In Myocardial Infarction major bleeding (2.
181 tal composite bleeding-access site bleeding, thrombolysis in myocardial infarction major/minor bleedi
182 or Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48) with a f
184 evention of Atherothrombotic Ischemic Events-Thrombolysis in Myocardial Infarction) (vorapaxar) and P
185 mpared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction) 54 trial randomiz
186 e against 2 validated bleeding scales: TIMI (Thrombolysis In Myocardial Infarction) and GUSTO (Global
188 tom-to-first device time, and baseline TIMI (Thrombolysis In Myocardial Infarction) flow 0/1 versus 2
189 e) and the primary safety endpoint was TIMI (Thrombolysis In Myocardial Infarction) major bleeding.
193 leeding defined according to the BARC, TIMI (Thrombolysis In Myocardial Infarction), GUSTO (Global Ut
194 days after PCI were defined according to the thrombolysis in myocardial infarction, Randomized Evalua
195 apy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51), rivaroxaban r
196 he subgroup with high thrombus burden (TIMI [Thrombolysis in Myocardial Infarction] thrombus grade >/
198 is helpful in identifying masses amenable to thrombolysis in patients with prosthetic valve dysfuncti
199 h accuracy and may guide the decision to use thrombolysis in patients with unknown time of stroke ons
200 V tPA enrolled in the Safe Implementation of Thrombolysis in Stroke (SITS) International Stroke Throm
202 rrhage within 7 days; Safe Implementation of Thrombolysis in Stroke Monitoring Study's (SITS-MOST) ha
203 the definition by the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST), whi
206 t include a vascular neurologist can provide thrombolysis in the prehospital setting faster than trea
207 able for molecular imaging of thrombosis and thrombolysis in vivo and represents a promising candidat
208 red with usual care alone (i.e., intravenous thrombolysis) in the management of acute ischemic stroke
209 nts with acute ischaemic stroke treated with thrombolysis, in relation to the presence of pre-treatme
210 to 44 min (29-60) in 2013; symptomatic post-thrombolysis intracerebral haemorrhages occurred in 28 o
217 trolled clinical trial comparing intravenous thrombolysis (IVT) alone with IVT and adjunctive intra-a
220 enchymal hematoma (PH) following intravenous thrombolysis (IVT) in ischemic stroke can occur either w
221 However, it is not known whether intravenous thrombolysis (IVT) is of added benefit in patients under
224 ntrol for the confounding variables of prior thrombolysis, location of occlusion, and operator expert
227 eceive ultrasound-assisted catheter-directed thrombolysis (N = 24) or conventional catheter-directed
234 enting as shock or arrest, emergent systemic thrombolysis or embolectomy is reasonable, while for low
235 ergency medical services, offers support for thrombolysis or immediate transfer for primary percutane
236 is, but other methods such as intra-arterial thrombolysis or mechanical thrombectomy can also be empl
237 artery occlusion" OR "retinal ischemia" AND "thrombolysis" OR "fibrinolysis" OR "tissue plasminogen a
238 te ischemic stroke and could be treated with thrombolysis, or had suffered a sudden cardiac arrest an
240 r-directed fibrinolysis, ultrasound-assisted thrombolysis, percutaneous mechanical thrombus fragmenta
244 thrombolysis (hereafter "pharmacomechanical thrombolysis") rapidly removes thrombus and is hypothesi
250 hrombosis treated with a fixed-dose catheter thrombolysis regimen, the addition of intravascular ultr
254 ost feared complications of the treatment is thrombolysis-related symptomatic intracerebral hemorrhag
257 with usual care, the use of ambulance-based thrombolysis resulted in decreased time to treatment wit
258 based patient stratification for intravenous thrombolysis, revolutionized by the landmark National In
260 randomized controlled trials of intravenous thrombolysis shows no statistically significant benefit
261 djustment for age, stroke severity, sex, and thrombolysis status showed that the distributions of 3-m
264 t up-to-date literature on imaging, systemic thrombolysis, surgical embolectomy, and catheter-directe
267 tion of pharmacomechanical catheter-directed thrombolysis to anticoagulation did not result in a lowe
268 MRI in acute stroke treatment (predominantly thrombolysis), to examine the assumptions and theories b
269 approach using anticoagulation, angioplasty/thrombolysis, transjugular intrahepatic portosystemic sh
270 nteraction between SPAN-100 index status and thrombolysis treatment (P < .001) revealing a reduction
271 cal trials but should probably not be denied thrombolysis treatment on the basis of such a profile al
272 teractions between SPAN-100 index status and thrombolysis treatment were observed for the 2 secondary
274 used individual patient data from the Stroke Thrombolysis Trialists' (STT) meta-analysis of randomise
277 hether ultrasound-assisted catheter-directed thrombolysis (USAT) is superior to anticoagulation alone
280 er adjuvant intracoronary therapies, such as thrombolysis, vasodilators, glycoprotein IIb/IIIa inhibi
281 thrombolysis, the proportion of golden hour thrombolysis was 6-fold higher after STEMO deployment (6
283 intermediate-risk pulmonary embolism trials, thrombolysis was associated with lower mortality (OR, 0.
287 Older adults were as likely to want stroke thrombolysis when unable to consent (78.1%) as when aske
288 have been devised to capture the benefits of thrombolysis while reducing its risks, but there is limi
289 tion time was a good predictor of successful thrombolysis with a cutoff point of <747 ms having a sen
290 s, thrombectomy was performed in addition to thrombolysis with intravenous alteplase, but benefits we
291 (IST-3) was a randomized controlled trial of thrombolysis with intravenous recombinant tissue plasmin
293 nset, to endovascular therapy (intraarterial thrombolysis with recombinant tissue plasminogen activat
295 ) trial was a randomized (1:1) comparison of thrombolysis with tenecteplase versus placebo in normote
296 to the current standard of care: intravenous thrombolysis with tissue-type plasminogen activator and
298 al ischaemic stroke eligible for intravenous thrombolysis within 4.5 h of onset were recruited from T
299 (chiefly of fatal intracerebral hemorrhage), thrombolysis within 6 h did not affect longer-term survi
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。